Abstract: The present invention provides KOC1-derived epitope peptides having the ability to induce cytotoxic T cells. The present invention further provides polynucleotides encoding the peptides, antigen-presenting cells presenting the peptides, and cytotoxic T cells targeting the peptides, as well as methods of inducing the antigen-presenting cells or CTLs. The present invention also provides compositions and pharmaceutical compositions containing them as an active ingredient. Further, the present invention provides methods of treating and/or preventing cancer, and/or preventing postoperative recurrence thereof, using the peptides, polynucleotides, antigen-presenting cells, cytotoxic T cells or pharmaceutical compositions of the present invention. Methods of inducing an immune response against cancer are also provided.

Abstract: Peptide vaccines against cancer are described herein. In particular, epitope peptides derived from the UBE2T that CTLs are provided. Isolated antigen-presenting cells with CTL inducibility and CTLs that target such peptides, as well as methods for inducing the antigen-presenting cell, or CTL are also provided. The present invention further provides pharmaceutical compositions containing such epitope peptides derived from UBE2T or polynucleotides encoding the polypeptides as active ingredients. Furthermore, the present invention provides methods for the treatment and/or prophylaxis of (i.e., preventing) cancers (tumors), and/or the prevention of a postoperative recurrence thereof, as well as methods for inducing CTLs, methods for inducing anti-tumor immunity, using the epitope peptides derived from UBE2T, polynucleotides encoding the peptides, or antigen-presenting cells presenting the peptides, or the pharmaceutical compositions of the present invention.

Abstract: Disclosed is a flame retardant resin composition in which relative to 100 parts by mass of the base resin, a silicone based compound is blended at a ratio of 0.1 to 10 parts by mass a fatty acid metal salt is blended at a ratio of 0.1 to 20 parts by mass, a flame retardant agent is blended at a ratio of 5 to 200 parts by mass, a hindered phenol based compound is blended at a ratio of 0.05 to 10 parts by mass, and a hindered amine based compound is blended at a ratio of 0.05 to 10 parts by mass. The hindered amine based compound has a group represented by the following formula (1). (R1 represents an alkyl or alkoxy group having 1 to 30 carbon atoms, and R2 to R5 each independently represent an alkyl group having 1 to 6 carbon atoms).

Abstract: The present invention provides CDCA1-derived epitope peptides having the ability to induce cytotoxic T cells. The present invention further provides polynucleotides encoding the peptides, antigen-presenting cells presenting the peptides, and cytotoxic T cells targeting the peptides, as well as methods of inducing the antigen-presenting cells or CTLs. The present invention also provides compositions and pharmaceutical compositions containing them as an active ingredient. Further, the present invention provides methods of treating and/or preventing cancer, and/or preventing postoperative recurrence thereof, using the peptides, polynucleotides, antigen-presenting cells, cytotoxic T cells or pharmaceutical compositions of the present invention. Methods of inducing an immune response against cancer are also provided.

Abstract: A flame retardant resin composition containing a polyolefin resin, a silicone compound, a fatty acid containing compound, aluminum hydroxide, and a triazine ring containing hindered amine compound. With respect to 100 parts by mass of the polyolefin resin, the silicone compound is blended in an amount of the range 0.5 to 10 parts by mass, the fatty acid containing compound is blended in an amount of the range 0.5 to 20 parts by mass, the aluminum hydroxide is blended in an amount of the range 1 to 60 parts by mass, and the triazine ring containing hindered amine compound is blended in an amount of the range 0.05 to 8 parts by mass or less. The triazine ring containing hindered amine compound may include an oxygen atom.

Abstract: The present invention provides URLC10-derived epitope peptides having the ability to induce cytotoxic T cells. The present invention further provides polynucleotides encoding the peptides, antigen-presenting cells presenting the peptides, and cytotoxic T cells targeting the peptides, as well as methods of inducing the antigen-presenting cells or CTLs. The present invention also provides compositions and pharmaceutical compositions containing them as an active ingredient. Further, the present invention provides methods of treating and/or preventing cancer, and/or preventing postoperative recurrence thereof, using the peptides, polynucleotides, antigen-presenting cells, cytotoxic T cells or pharmaceutical compositions of the present invention. Methods of inducing an immune response against cancer are also provided.

Abstract: The present invention provides isolated peptides or the fragments derived from SEQ ID NO: 45, which bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL). The peptides may include the above mentioned amino acid sequence with substitution deletion, or addition of one, two, or several amino acids sequences. The invention also provides pharmaceutical compositions including these peptides. The peptides of this invention can be used for diagnosing or treating cancer.

Abstract: The present invention provides URLC10-derived epitope peptides having the ability to induce cytotoxic T cells. The present invention further provides polynucleotides encoding the peptides, antigen-presenting cells presenting the peptides, and cytotoxic T cells targeting the peptides, as well as methods of inducing the antigen-presenting cells or CTLs. The present invention also provides compositions and pharmaceutical compositions containing them as an active ingredient. Further, the present invention provides methods of treating and/or preventing cancer, and/or preventing postoperative recurrence thereof, using the peptides, polynucleotides, antigen-presenting cells, cytotoxic T cells or pharmaceutical compositions of the present invention. Methods of inducing an immune response against cancer are also provided.

Abstract: The present invention provides KOC1-derived epitope peptides having the ability to induce cytotoxic T cells. The present invention further provides polynucleotides encoding the peptides, antigen-presenting cells presenting the peptides, and cytotoxic T cells targeting the peptides, as well as methods of inducing the antigen-presenting cells or CTLs. The present invention also provides compositions and pharmaceutical compositions containing them as an active ingredient. Further, the present invention provides methods of treating and/or preventing cancer, and/or preventing postoperative recurrence thereof, using the peptides, polynucleotides, antigen-presenting cells, cytotoxic T cells or pharmaceutical compositions of the present invention. Methods of inducing an immune response against cancer are also provided.

Abstract: In a flame retardant resin composition containing a polyolefin resin, a silicone-based compound blended at a ratio of 1.5 parts by mass or more and 20 parts by mass or less relative to 100 parts by mass of the polyolefin resin, a fatty acid containing compound blended at a ratio of 5 parts by mass or more and 20 parts by mass or less relative to 100 parts by mass of the polyolefin resin, and an inorganic flame retardant blended at a ratio of 5 parts by mass or more and 40 parts by mass or less relative to 100 parts by mass of the polyolefin resin, the decomposition onset temperature of the inorganic flame retardant is lower than the decomposition onset temperature of the silicone-based compound.

Abstract: A flame retardant resin composition comprises a polyolefin resin, calcium carbonate particles blended at a ratio of 5 pts. mass to 80 pts. mass, aluminum hydroxide blended at a ratio of 50 pts. mass to 125 pts. mass, a silicone-based compound blended at a ratio of more than 1 pt. mass and 10 pts. mass or less, a fatty acid-containing compound blended at a ratio of 3 pts. mass to 20 pts. mass, and a zinc-containing inorganic compound blended at a ratio of 1 pt. mass to 7 pts. mass, all relative to 100 pts. mass of the polyolefin resin. In the flame retardant resin composition, the calcium carbonate particles and the aluminum hydroxide are blended in total at a ratio of 55 pts. mass to 130 pts. mass relative to 100 pts. mass of the polyolefin resin.

Abstract: Disclosed is a flame retardant resin composition comprising: a polyolefin resin; a silicone-based compound blended at a ratio of 3 parts by mass or more and 20 parts by mass or less relative to 100 parts by mass of the polyolefin resin; a fatty acid containing compound blended at a ratio of 5 parts by mass or more and 20 parts by mass or less relative to 100 parts by mass of the polyolefin resin; calcium carbonate blended at a ratio of 10 parts by mass or more and less than 100 parts by mass relative to 100 parts by mass of the polyolefin resin; and aluminum hydroxide blended at a ratio of 5 parts by mass or more and 60 parts by mass or less relative to 100 parts by mass of the polyolefin resin.

Abstract: Disclosed is a flame retardant resin composition in which relative to 100 parts by mass of the base resin, a silicone based compound is blended at a ratio of 0.1 to 10 parts by mass a fatty acid metal salt is blended at a ratio of 0.1 to 20 parts by mass, a flame retardant agent is blended at a ratio of 5 to 200 parts by mass, a hindered phenol based compound is blended at a ratio of 0.05 to 10 parts by mass, and a hindered amine based compound is blended at a ratio of 0.05 to 10 parts by mass. The hindered amine based compound has a group represented by the following formula (1). (R1 represents an alkyl or alkoxy group having 1 to 30 carbon atoms, and R2 to R5 each independently represent an alkyl group having 1 to 6 carbon atoms).

Abstract: Peptide vaccines against cancer are described herein. In particular, epitope peptides derived from the UBE2T that elicit CTLs are provided. Isolated antigen-presenting cells with CTL inducibility and CTLs that target such peptides, as well as methods for inducing the antigen-presenting cell, or CTL are also provided. The present invention further provides pharmaceutical compositions containing such epitope peptides derived from UBE2T or polynucleotides encoding the polypeptides as active ingredients. Furthermore, the present invention provides methods for the treatment and/or prophylaxis of (i.e., preventing) cancers (tumors), and/or the prevention of a postoperative recurrence thereof, as well as methods for inducing CTLs, methods for inducing anti-tumor immunity, using the epitope peptides derived from UBE2T, polynucleotides encoding the peptides, or antigen-presenting cells presenting the peptides, or the pharmaceutical compositions of the present invention.

Abstract: The present invention provides isolated peptides or the fragments derived from SEQ ID NO: 45, which bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL). The peptides may include the above mentioned amino acid sequence with substitution deletion, or addition of one, two, or several amino acids sequences. The invention also provides pharmaceutical compositions including these peptides. The peptides of this invention can be used for diagnosing or treating cancer.

Abstract: Disclosed is a flame retardant resin composition containing a polyolefin resin, a silicone compound, a fatty acid containing compound, calcium carbonate, and a triazine ring containing hindered amine compound. In this composition, relative to 100 parts by mass of the polyolefin resin, the silicone compound is blended at a ratio of 1.5 parts by mass or more and 10 parts by mass the fatty acid containing compound is blended at a ratio of 3 parts by mass or more and 20 parts by mass, the calcium carbonate is blended at a ratio of 10 parts by mass or more and less than 120 parts by mass, the triazine ring containing hindered amine compound is blended at a ratio of 0.05 part by mass or more and less than 10 parts by mass, and the triazine ring containing hindered amine compound includes an oxygen atom.

Abstract: In a flame retardant resin composition containing a polyolefin resin, a silicone-based compound blended at a ratio of 1.5 parts by mass or more and 20 parts by mass or less relative to 100 parts by mass of the polyolefin resin, a fatty acid containing compound blended at a ratio of 5 parts by mass or more and 20 parts by mass or less relative to 100 parts by mass of the polyolefin resin, and an inorganic flame retardant blended at a ratio of 5 parts by mass or more and 40 parts by mass or less relative to 100 parts by mass of the polyolefin resin, the decomposition onset temperature of the inorganic flame retardant is lower than the decomposition onset temperature of the silicone-based compound.

Abstract: Provided is a flame retardant resin composition including a base resin, calcium carbonate particles that are incorporated at a proportion of 10 parts by mass or more relative to 100 parts by mass of the base resin, a silicone-based compound that is incorporated at a proportion of more than 1 part by mass relative to 100 parts by mass of the base resin, and a fatty acid-containing compound that is incorporated at a proportion of more than 3 parts by mass relative to 100 parts by mass of the base resin. The average particle size of the calcium carbonate particles is 0.7 ?m or larger.

Abstract: The present invention provides isolated peptides or the fragments derived from SEQ ID NO: 45, which bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL). The peptides may include the above mentioned amino acid sequence with substitution deletion, or addition of one, two, or several amino acids sequences. The invention also provides pharmaceutical compositions including these peptides. The peptides of this invention can be used for diagnosing or treating cancer.

Abstract: Isolated peptides derived from SEQ ID NO: 50 and fragments thereof that bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL) and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines are described herein. The inventive peptides encompasses both the above mentioned amino acid sequences and modified versions thereof, in which one, two, or several amino acids sequences substituted, deleted, added or inserted, provided such modified versions retain the requisite cytotoxic T cell inducibility of the original sequence. Further provided are nucleic acids encoding any of the aforementioned peptides as well as pharmaceutical agents, substances and/or compositions that include or incorporate any of the aforementioned peptides or nucleic acids.